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Abstract
Methicillin-resistant S. aureus (MRSA) has emerged as the most common hospital-acquired pathogen
and is associated with increased morbidity and mortality compared with other strains. Vancomycin
has been the cornerstone of treatment of patients with serious MRSA infections for some decades
and while more than 99% of clinical S. aureus isolates remain susceptible to vancomycin, we are
beginning to see strains of MRSA with reduced susceptibility. This review discusses this phenomenon,
the predictors of infection with such forms of MRSA, and current and future management options.
Introduction
Methicillin-resistant S. aureus (MRSA) has emerged as the
most common hospital acquired pathogen, accounting
for >60% of the clinical S. aureus isolates recovered in US
intensive care units [1]. Infection with MRSA is asso-
ciated with increased morbidity, requirement of longer
duration of antibiotic therapy, higher healthcare costs,
prolonged hospitalization and an increased risk of death
[2,3]. This risk is more pronounced in patients who have
been treated sub-optimally, either with an ineffective
antibiotic and/or inadequate surgical intervention.
Vancomycin has been the cornerstone of treatment of
patients with serious MRSA infections. Consequently,
vancomycin use has been increasing since the mid-
1980’s, resulting in the emergence of MRSA with reduced
susceptibility to vancomycin. In patients with S. aureus
bacteremia, higher vancomycin minimum inhibitory
concentrations (MICs) have been associated with pro-
longed bacteremia or increased mortality [4]. While
vancomycin non-susceptible strains (see Table 1), in the
form of intermediate-resistant S. aureus, (VISA, vanco-
mycin MIC 4-8 mg/L) remain rare and vanA-mediated
vancomycin-resistantS.aureus(VRSA,vancomycinMIC>
16 mg/L) are limited to a handful of reported cases, the
rising MICs of vancomycin among vancomycin suscep-
tible S. aureus, referred to as the ‘vancomycin MIC creep’,
has caused a re-evaluation of vancomycin susceptibility
criteria in cases of complicated infections like bacteremia
and/or pneumonia [4,5].
This report will discuss the phenomenon of vancomycin
MIC creep in S. aureus, its potential association with
decreased vancomycin efficacy, the predictors of infec-
tions with MRSA with high vancomycin MIC, and briefly
review the current and future management options.
Vancomycin – the early years
Vancomycin is a complex tricyclic glycopeptide that was
first isolated from Amycolatopsis orientalis found in a soil
sample from Borneo in the mid 1950s that has activity
againstmostclinicallyrelevantGram-positivepathogens[6].
In 1958, vancomycin was introduced for clinical use
against penicillin-resistant S. aureus, but for the first
25 years after introduction, its use remained limited to
patients with severe beta-lactam allergy and with MRSA
infection, which were infrequent prior to 1980. However,
the 1980s were marked by a surge in the use of
cephalosporin and quinolone antibiotics in hospitals,
which paralleled the emergence of methicillin resistance
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quently S. aureus. During this early period, vancomycin
dosing was centered around avoidance of nephrotoxicity
and dosing convenience rather than efficacy or prevention
of developing resistance, with target serum trough
concentrations of 5-10 mg/L. In contrast, recent consensus
guidelines have recommended troughs of 15-20 mg/L in
the treatment of serious MRSA infections, not only for
increasing pharmacodynamic exposure to improve in vivo
efficacy but also to prevent selection of S. aureus strains
with higher MICs that have been demonstrated in vitro in
vancomycin concentrations < 10 mg/L [7]. It is important
to realize that a robust risk-benefit analysis for pushing
serum concentrations of vancomycin to these heights is so
far lacking.
Vancomycin susceptibility testing
For antimicrobials, various laboratory methods of
susceptibility testing against strains of bacteria are used
topredictclinicalresponse.Thesimplestoftheseassaysis
the “MIC”, which refers to the lowest concentration of
antibiotic that inhibits visible growth of a standard
inoculum size of bacteria (generally 10
4 cfu for staphy-
lococci) after overnight incubation in Mueller-Hinton
broth. A result of “susceptible” by a clinical microbiology
laboratory is considered to be predictive of a satisfactory
clinical response whereas “nonsusceptible” or “resistant”
predicts failure. While beyond the scope of this article,
readers must appreciate that establishing these MIC so-
called “breakpoints” for strains that are susceptible,
intermediate, and resistant to antibiotics is controversial
and wrought with laboratory oversimplifications of a
very complex host-pathogen-antibiotic relationship. In
short, microbiological breakpoints (maximum MIC
thresholds for predicting successful treatment) are
established by combining data of MIC distributions of
groups of clinical strains and available pharmacody-
namic and pharmacokinetic information, but not on any
data that correlates clinical response to MIC. Further-
more, the MIC measures inhibition of growth, not killing
potency of an antibiotic. Such methods are much more
time consuming and are rarely used and/or available to
clinicians in a timely manner. Finally, in vitro assays of
susceptibility like MIC measurements completely ignore
any potential interaction of the antibiotic with innate
host defense mechanisms that may occur in vivo.
Various tests and methodologies with variable sensitivity
and specificity are available to measure vancomycin
MICs. Broth microdilution is considered to be the gold
standard for measuring vancomycin MIC. However,
broth microdilution can be a cumbersome test and is
not used routinely in clinical laboratories. Since it is
reliant on a two-fold dilution, it offers limited quanti-
tative information. Also, agar disc diffusion is not a
suitable test for large molecules like vancomycin and
moreover it does not measure the MIC directly and
cannot detect VISA isolates. Currently, most clinical
laboratories use Etest and automated susceptibility tests
for measuring the vancomycin MIC. However, auto-
mated testing has been associated with underestimation
of vancomycin MIC when compared to Etest and broth
microdilution [8]. In 2006, CLSI revised the suscept-
ibility breakpoints for vancomycin in response to
evidence that vancomycin was poorly effective against
MRSA isolates with MIC > 4 mg/L [4].
Vancomycin resistance and heteroresistance
VRSA
VRSA (vancomycin resistant S. aureus) isolates remain
rare and sporadic. Since the first report in 2002, there
have been 13 confirmed cases of VRSA [9] from US, and
one each from India and Iran). A few existing factors that
seem to predispose patients to VRSA infection include
prior MRSA and vancomycin-resistant enterococcal
infections or colonization, underlying chronic medical
conditions, and previous extensive treatment with
vancomycin [10].
VISA and hVISA
S.aureus isolateswithbroth microdilutionMIC4-8μg/mL
aretermedasVISA.Thisdefinitionhasbeenexcludedfrom
the newEUCASTbreakpoints which definean isolate with
brothmicrodilutionMIC≥4μg/mLasresistantratherthan
Table 1: Clinical Laboratory and Standards Institute (CLSI) susceptibility breakpoints for vancomycin
Pathogen Abbreviation Susceptibility
profile
MIC
(μg/mL)
Vancomycin-susceptible S. aureus VSSA susceptible <2
Heteroresistant S. aureus with intermediate susceptibility to vancomycin
or glycopeptide
hVISA or hGISA heteroresistant 1-2
a
S. aureus with intermediate susceptibility to vancomycin or glycopeptide VISA intermediate 4-8
Vancomycin-resistant S. aureus VRSA resistant >16
b
aconsists of subpopulations (≤ 1 in 1,000,000) that may grow in media containing >2 μg/mL of vancomycin.
brequires backup primary testing with 6μg/mL of vancomycin on an overnight plate.
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VISA and VRSA is the occurrence of S. aureus isolates
exhibitingheteroresistance tovancomycin.hVISA (hetero-
resistant VISA) is defined as a vancomycin-susceptible
S. aureus (VSSA) strain that upon subculture produces
sub-colonies with MIC in the VISA/VRSA range at the
frequency of ≥1×10
6 according to population analysis
profile (PAP) (Figure 1). Quantitative definitions used for
hVISA are an AUC (area under the curve) ratio of ≥ 0.9 of
the AUC oftypestrain Mu3 (PAP/AUC)ormodifiedhigh-
inoculum Etest read at 48 h [11,9].
The hVISA phenotype is considered to be a precursor to
VISA, and falls on the same continuum on the hetero-
resistancespectrum.ThefirstcaseofhVISAwasreportedin
Japan in 1996. Current reported prevalence of hVISA is
variable (0-74%) because of difficulty of detection,
cumbersome and non-standardized detection methods,
variable selective vancomycin pressure, and instability of
the phenotype once some isolates are frozen and stored
[9].ThemainriskfactorsforinfectionscausedbyVISAand
hVISA strains are prior MRSA infection with high bacterial
load (endocarditis, deep abscess, prosthetic joint infec-
tions) and prior vancomycin exposure (particularly a low
serum concentration). Nosocomial spread and rare out-
breaks caused by hVISA or VISA strains have also been
reported.
The above discussion points out an obvious inherent
flaw in establishing a microbiological breakpoint for
vancomycin that correlatescleanly with clinical response.
Vancomycin heteroresistance in hVISA is characterized
by the existence of subpopulations of organisms among
vancomycin-susceptible strains that are able to grow in
concentrations of vancomycin in the range of intermedi-
ate-resistant organisms. This property is present in all
staphylococci but in varying degrees. If the proportion of
organisms in the bacterial population is sufficiently high
to be detected with standard low inocula of susceptibility
testing, they may be detected and appropriately con-
sidered nonsusceptible. However, if the proportion of
organisms in a bacterial population that can grow in
vancomycin >2 mg/L is below the frequency of the
testing inoculum density, then the strain will be
characterized as susceptible by standard susceptibility
testing. Infections with high bacterial load (e.g. pneu-
monia, endocarditis, abscess) will not only have a high
risk for vancomycin treatment failure but also risk the
rapid development of vancomycin intermediate resis-
tance (VISA), especially if vancomycin is under-dosed
and the organisms are exposed to vancomycin concen-
trations <10g/L [12]. This latter process is simply
“enriching” the already present bacterial population for
vancomycin-resistant subspecies to the point where
subsequent susceptibility testing, after selection, will
appropriately characterize these strains as VISA.
It is important to also consider that in situations where
the infection is characterized by low bacterial inocula
(e.g. UTI, simple cellulitis without abscess), vancomycin
heteroresistance, and, therefore, the MIC creep, is likely
to be less clinically relevant, if at all. The higher the
vancomycin MIC, the more likely that a strain will
exhibit subpopulations that can be grown in ranges of
vancomycin concentrations comparable to vancomycin
non-susceptible strains (Figure 2). Therefore, a high-
inoculum infection like endocarditis caused by a
vancomycin-susceptible S. aureus with an MIC of 2 mg/L
is much more likely to fail vancomycin therapy than a
low-inoculum infection such as a surgical wound
infection without an abscess where the vancomycin
MIC is lower. Both strains are vancomycin “susceptible”,
but clinical susceptibility to the drug is different in each
of these cases.
Vancomycin Pharmacodynamics
Based on neutropenic mouse models, in vitro studies and
limited data from human studies, the AUC/MIC ratio has
been used as a preferred parameter for measuring the
effectiveness of vancomycin in treating S. aureus infec-
tions [13,14]. A specific AUC/MIC threshold of 400 has
been advocated as a target to achieve clinical effective-
ness with vancomycin, based on the initial clinical data
from pneumonia [15] and more recent data from
bacteremia [16]. These considerations superimposed
on the vancomycin MIC creep have provided circum-
stantial evidence, without clinical trial validation, to
support higher vancomycin trough concentrations in the
Figure 1. Population analysis amoung hVISA and VISA of
heterogeneous resistance to vancomycin
Populationanalysisdemonstratingvaryingdegreesofheterogeneousresistance
to vancomycin among hVISA and VISA, relative to the more homogenous
patterns seen in vancomycin-susceptible S. aureus (VSSA) and vanA-mediated
vancomycin resistance in VRSA. (Antimicrob Agents Chemother,2 0 0 3 ,47:3040-
5, 10.1128/AAC.47.10.3040-3045.2003, reproduced/amended with permis-
sion from American Society for Microbiology [11].)
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beensuggestedthattheprobabilityofattainingthisratiois
approximately 100% only in isolates with MIC≤0.5 mg/L
and the probability falls to 0% in isolates with MIC of
2mg/L [17]. Based on simulated models, it has further
been reported that a daily dose of 3-4 gm of vancomycin
will be required to provide 90% probability of attaining
the target AUC/MIC of 400 for an isolate with MIC 1mg/L
[18].
While vancomycin has traditionally been considered a
bactericidal agent, its potency is reduced to bacteriostatic
levels in the setting of high-inoculum infections,
stationary growth phase, or in an anaerobic environ-
ment. Decreased bactericidal activity (vancomycin toler-
ance) has been associated with higher vancomycin MIC.
However, not all MRSA strains with a vancomycin MIC
of 2mg/L are vancomycin tolerant. Vancomycin toler-
ance has been seen in 15% of wild-type MRSA strains
compared with 74% of hVISA strains and 100% of VISA
and VRSA strains [19]. This decreased bactericidal activity
of vancomycin has been shown to be associated with
poor clinical outcomes in bacteremia and can be
independent of the MIC values [20]. Receipt of any
vancomycin within 30 days predicts bacteriostatic
activity among MRSA bacteremia isolates, whereas
vancomycin-naïve patients with MRSA bacteremia can
be expected to have isolates against which vancomycin is
bactericidal [21].
Phenotypic changes associated with decreased
vancomycin susceptibility
VISA has altered cellular physiology as a result of
cumulative effects of mutations and/or modulation of
regulatory systems. This altered physiology appears to
change cell-wall metabolism in such a way as to result in
increased numbers of D-Ala-D-Ala residues, which serve
as dead-end binding sites for vancomycin. In addition,
evaluation of S. aureus with reduced vancomycin
susceptibility and isogenic vancomycin-susceptible pro-
genitors showed cell walls with reduced peptidoglycan
cross-linking, reduced cell-wall turnover, and reduced
autolysis, causing considerable morphological cell-wall
thickening. This altered cell wall results in a reduced
diffusion coefficient of vancomycin, sequestration of
vancomycin within the cell wall by these false targets,
and prevention of vancomycin reaching its site of action
[22-24].
Vancomycin ‘MIC creep’ and clinical significance
Within the populations of S. aureus that are considered to
be susceptible, a changing pattern of vancomycin MICs
has been observed in some centers, demonstrating an
overall population drift in the clinical isolates of S. aureus
towardsreducedvancomycinsusceptibility.Thisphenom-
enon of “vancomycin MIC creep” varies considerably
aroundtheworldandissummarizedinTable2.However,
it is important to point out that this is not universal and
some centers have noted no changes or even reductions in
vancomycin MIC creep (GS, unpublished observations).
Thus, when large numbers of S. aureus samples are pooled
together and analyzed from multiple centers, as in the
SENTRY database study, center to center heterogeneity
leadstoanetneutralizationeffect,withnooverallchanges
and clinical factors between study sites, including selective
pressuregeneratedbyhigh-dose versustraditionaluse and
dosing of vancomycin, severity of illness in the patient
populations with different co-morbid conditions, differ-
ence in medical and surgical therapy of invasive S. aureus
infections, and variation in susceptibility testing methods
[25]. This variation is further confounded by the
emergence of community-acquired MRSA and its pre-
valence in hospital settings. Community-acquired MRSA
historically has a lower vancomycin MIC than MRSA from
hospitals, presumably because of reduced vancomycin
exposure, although virulence selection pressure
may also play a role (discussed later). Furthermore, one
needs to take reporting bias into account, whereby a
Figure 2. Heteroresistance to vancomycin therapy amoung
S. aureus isolates
Fraction of hVISA (black) present among total S. aureus stratified by
vancomycin MIC. (reproduced from Fred C. Tenover, Robert C. Moellering,
Jr., The Rationale for Revising the Clinical and Laboratory Standards
Institute Vancomycin Minimal Inhibitory Concentration Interpretive Criteria
for Staphylococcus aureus, Clin Infect Dis, 2007, 44:1208-15 by permission of
Oxford University Press [4].)
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invancomycinsusceptibiltyobserved[19].Thesevariatio-
ns are accounted for by differences in the epidemiologicaldisproportionately higher numbers of centers with
observed increases in vancomycin MIC may report their
positiveresultsintheliterature,asopposedtothenegative
results from centers without this phenomenon. In short,
the relevance of the vancomycin creep for individual
clinicians, pharmacists, and microbiologists can only be
assessed by the evaluation of their local susceptibility
profiles, not published observations of others.
Infections caused by S. aureus isolates with higher
vancomycin MIC, even those in the susceptible range,
have shown to be associated with various poor clinical
outcomes, including delayed early response, increased
mortality, increased rate of relapse, prolongedhospital stay
or overall increased cost of hospitalization (see Table 3).
Vancomycin MIC creep has been observed in both
methicillin-susceptible and -resistant S. aureus isolates
[26,27]. Interestingly, elevated vancomycin S. aureus MIC
has been associated with increased mortality in patients
with methicillin-susceptible S.aureus infections when they
are treated with either vancomycin or flucloxacillin [27].
Predictors for vancomycin resistance
Recent guidelines have suggested considering alternative
antibiotics in complicated MRSA infection when vanco-
mycin MIC is ≥2 μg/mL [28]. Various studies have
attempted to identify patients at risk of infections with
S. aureus with higher vancomycin MIC. This is important,
as many hospitals estimate vancomycin MIC using
automated methods and do not routinely provide a
measured MIC value for the medical record. Also up to
90% of MRSA isolates with a MIC of 2μg/mL can be
missed by some automated systems [11]. Infections
caused by MRSA with higher vancomycin MIC are seen in
patients with recent exposure to vancomycin within one
Table 2: Summary of studies evaluating evidence of increasing Vancomycin MIC and MIC Creep in S. aureus (all MIC in μg/mL)
Study Study type MIC method Evidence of
MIC creep
Comments
Wang
2006 [26]
2000-2004
Single center (US)
6003 SA, All clinical specimens
BMD Yes Shift of MIC from <0.5 to 1.0 over 5 year period.
% isolates with MIC>1: 2000 (19.9%) vs. 2004 (70.4%).
MIC creep noted in both MSSA and MRSA isolates.
Golan
2006 [8]
2002-2005
Single center (US)
BMD Yes Geometric mean vancomycin MIC increased from 0.9 to
1.4 over the study period.
% isolates with MIC >0.5 increased for 67% to 96%,
% isolates with MIC= 2 increased form 13% to 51%
Isolates with MIC= 2 were frequently missed by
automated systems.
Robert
2006 [43]
1983-2002
Single center (France)
1445 MRSA, All clinical specimens
Etest Yes Vancomycin MIC geometric mean increased from 1.56 in
1983 to 2.41 in 2002
Jones
2006 [19]
1998-2003 SENTRY database
(>50 worldwide centers)
35,485 SA, 5902 CoNS
All clinical specimen
BMD No No detected MIC creep in all gram positive organisms.
Vancomycin tolerance was noted in wt MRSA (15.2%),
VISA (73.9%), VISA (100%), VRSA (100%) with significant
associated decrease in bactericidal activity.
Steinkraus
2007 [44]
2001-2005
Single center (US)
662 MRSA Blood Culture
Etest Yes 1.5-fold increase in the geometric mean vancomycin MIC.
% isolates with MIC=1 2001(16%) vs. 2005(69%).
% isolates with MIC>1 2001 (0%) vs. 2005(7%).
Holmes
2008 [45]
1999-2006
Single center ( US)
240 MRSA Blood Culture
BMD No No change MIC and bactericidal activity of vancomycin in
the pre-therapy isolates over the study period.
Alos
2008 [46]
2002-2006
Single center (Spain)
3141 SA, (566 MRSA)
All clinical specimen
BMD No In an area of low vancomycin consumption, no statistically
significant difference in 2 MIC groups (≤1 vs. ≥ 2).
Sader
2009 [47]
2002-2006
9 medical centers (US)
1800 MRSA Blood cultures
BMD Possible/No Geometric mean data showed a possible very low level
MIC creep in 3/9 centers not evident on modal MICs.
No overall increase in the resistance noted.
Musta
2009 [29]
1996-2006 period
Single center (US)
489 blood cultures
Etest No % isolates with vancomycin MIC≤1, 1.5, 2, 3 and % isolates
with hVISA was unchanged over the 11 year period
Karas
2010 [48]
1998-2007
2 medical centers (UK)
259 MRSA Blood cultures
Agar Dilution Possible Increase in the % isolates with MIC>0.75
1998-2001 (4.4%) vs. 2002-04(4.9%) vs. 2005-07 (10.8%)
Ho
2010 [49]
1997-2008
5 hospitals (Hong Kong)
247 MRSA Blood cultures
Etest Yes Increase in the % isolates with MIC=1
1997-99(10.8%) vs. 2004(21.6%) vs. 2006-08 (38.3%)
Abbreviations: BMD, broth microdilution; MIC, minimum inhibitory concentration; MSSA, Methicillin-susceptible S. aureus; MRSA, Methicillin-resistant S.
aureus; VISA, vancomycin-intermediate S. aureus; VRSA vancomycin-resistant S. aureus.
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Study Study type Clinical Isolates MIC method Clinical outcomes
Moise-B
2004 [50]
1998-2001
Multicenter (US)
122 MRSA infections
(25 blood cultureD)
BMD Increased failure rate was associated with higher
MIC: 22 % (MIC 0.5) vs. 27% (MIC 1.0) vs. 51 % (MIC
2) and in patients with bacteremia of unknown
origin, endocarditis, and respiratory infections.
Sakoulas
2004 [20]
1998-2001
Multicenter (US)
30 MRSA blood cultures BMD Treatment success with vancomycin was associated
with lowerMIC: 55.6 % (MIC≤0.5 vs. 9.5 % (MIC 1-2)
and increased vancomycin killing (OR 10.73).
No significant relation between vancomycin MIC and
vancomycin bactericidal activity.
Rhee
2005 [51]
1994-1999
Single center (US)
2002-2004
171 SA blood culture/
osteomyelitis
52 clinical isolates
N/A Decrease vancomycin susceptibility based on MBC
data.
% isolates with MBC≥1.6mcg/mL increased from 8%
in 1994 to 30% in 1999.
From 2002-2004, increased proportion of isolates
with MBC≥2.
Maclayton
2006 [52]
2001-2003
Single center (US)
50 MRSA blood culture in
HD patients
Vitek Increased mortality in patients with higher vanco-
mycin MIC: 35 %( MIC 1-2) vs. 24 % ( ≤ 0.5) vs 15%
(controls).
Increased cost of hospitalization was seen in group
with MRSA infections with higher vancomycin MIC.
Risk factors of infection with higher MIC were
surgery within last 6 months and ICU admission.
Hidayat
2006 [53]
2004-2005
Single center (US)
95 MRSA infections Etest Overall response rate at end of therapy was lower in
patients with infection with MRSA with higher MIC:
62% (MIC 2) vs. 85% (MIC≤1).
Poor outcomes were associated with MIC 2 (OR
6.02) and severity of underlying illness (OR 3.14).
Increased nephrotoxicity was seen with higher
serum trough levels (15-20), duration of vancomycin
treatment and use of concomitant nephrotoxic
agents.
Neoh
2007 [54]
1998-2005
Single center (Japan)
22 MRSA blood cultures Agar dilution Significant difference in response was seen in patients
with lower vancomycin susceptibility as expressed
by area under curve (AUC) of population analysis.
Soriano
2008 [40]
1991-2005
Single center (Spain)
414 MRSA blood cultures Etest Higher mortality associated with increased vanco-
mycin MIC: OR 2.86 (MIC 1.5) and OR 6.37 (MIC 2)
vs. OR 3.62 (inappropriate therapy).
Vancomycin MIC=2 was associated with decreased
risk of shock (OR 0.33)
Lodise
2008 [30]
2005-2007
Single center (US)
92 MRSA blood cultures Etest 2.4 fold increase in the risk of failure and longer
hospital stay associated with vancomycin MIC≥1.5.
Ability to achieve primary trough levels of 15mg/L
was not associated with increased probability of
success irrespective of MIC.
Musta
2008 [29]
1996-2006
Single center (US)
489 MRSA blood culture
Mortality results on 285
isolates
Etest Increased mortality with high vancomycin MIC:
19.4% (MIC≤1 vs. 27% (MIC 1.5 vs. 47.6% (MIC≥ 2).
hVISA seen in 14% of isolates and was not associated
with increased mortality.
Yoon
2010 [55]
2006-2009
Single center (Korea)
96 MRSA blood cultures Vitek 2 Persistent bacteremia associated with vancomycin
MIC-2(OR 6.23), retention of medical devices (OR
10.35) and MRSA infection at more than two sites
(OR 10.24).
Increased MRSA bacteremia related mortality asso-
ciated with higher vancomycin MIC: 50 % (MIC 2) vs.
19% (MIC≤1).
Wang
2010 [56]
2006
Single center, (Taiwan)
126 MRSA blood culture BMD Increased mortality at day 14 and 30 was associated
with vancomycin MIC=2 (OR 3.76).
Vancomycin MIC=2 was seen in patients with
hospitalization >2 months ago (OR 4.56) and ICU
admission prior to developing bacteremia (OR 4.83).
Haque
2010 [31]
2006-2007
4 US centers
158 MRSA pneumonia Etest Risk of death was increased 2.97 fold for increase of
1 μg/mL of vancomycin MIC. Heteroresistance was
seen in 21.5% of isolates and was not associated with
increased mortality.
Choi
2011 [57]
2008-2009
Single center (Korea)
70 MRSA pneumonia Etest Higher vancomycin MIC was associated with
decreased early response 35.3 % (MIC≥1.5 vs. 63.9%
(MIC≤1) and increased risk of relapse at day 28 29.6
% (MIC≥1.5 vs. 6.9% (MIC≤1).
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tion, surgery within last 6 months and those with blood
stream infections prior to admission in intensive care
units [29-32]. One recent study attempted to produce a
score for high vancomycin MIC in MRSA blood stream
infections using factors like age, prior vancomycin
exposure, history of MRSA bacteremia, chronic liver
disease, and presence of non-tunneled central venous
catheter as predictors. Using these factors and the local
rate of high vancomycin MIC, different cut-off points can
be established and effectivly used to rule in or rule out an
infection with an MRSA isolate with high vancomycin
MIC and therefore help in selecting the early and empiric
effective anti-MRSA therapy [33].
Vancomycin “cross-resistance creeps”
Due to the complex nature of the mechanism of
vancomycin heteroresistance, which represents a sum-
mation of a combination of genetic and gene expression
events, it would be expected that the vancomycin MIC
creep would influence not only susceptibility to vanco-
mycin but other antibiotics as well. This hypothesis has
been validated extensively in the literature with dapto-
mycin, a cyclic lipopeptide of a different antibiotic class
and mechanism of action. S. aureus strains with higher
vancomycin MICs also tend to have higher daptomycin
MICs [34]. As one “climbs the ladder” of vancomycin
resistance, increasing daptomycin nonsusceptibility is
observed, with about 50% of VISA being daptomycin
nonsusceptible [35]. This selection of daptomycin
nonsusceptibility by vancomycin occurs without expo-
sure to daptomycin [36]. While the molecular mechan-
ism(s) remain unknown, this cross-heteroresistance
between vancomycin and daptomycin has important
clinical implications. First, it further underscores the
danger of vancomycin underdosing, as selection of
hVISA and VISA in an infection like endocarditis,
which contains a large number of organisms. Secondly,
given the less likely scenario of daptomycin selecting for
vancomycin heteroresistance, debates have surfaced
towards using daptomycin rather than vancomycin
as first line therapy, particularly in healthcare settings
where vancomycin MICs of 2 mg/L are expected. While
microbiologically sound, daptomycin is much more
costly, and consequently physicians may be reluctant to
use it during the first 24-72 hour window where blood
cultures are pending. Third, use of daptomycin in salvage
of vancomycin failure in MRSA bacteremia has been
suggested at higher than approved doses of 8 mg/kg/day
rather than the approved 6 mg/kg/day dose [28]. While
unproven in benefit, higher doses are recommended
when prior vancomycin has already reduced the potency
of daptomycin, both in terms of increasing MIC and
tolerance. Nevertheless, case reports demonstrate that the
prior selection of daptomycin heteroresistance by van-
comycin is not universally overcome with high-dose
daptomycin monotherapy, and combination therapy
with aminoglycosides is recommended. We have
reported great success using daptomycin in combination
with antistaphylococcal beta-lactams in the most recal-
citrant cases of MRSA bacteremia [37].
Vancomycin heteroresistance and implications
for virulence
Knowledge of the innate host response has revealed that
it consists, in part, of antimicrobial peptides produced by
various cell types (e.g. cathelicidins, defensins, platelet
microbicidal proteins) that serve to kill invasive patho-
gens. These antimicrobial peptides can be viewed in
simple terms as endogenous antibiotic molecules pro-
duced by mammals. Thus, it would be conceivable that
cross-resistance may occur between prokaryotic antibio-
tics and the antimicrobial peptides of mammals. While
this area remains largely unexplored, evidence is emer-
ging which demonstrates cross-resistance between plate-
let microbicidal proteins (cationic peptides produced by
platelets) and vancomycin and daptomycin. Platelet
microbicidal protein is believed to be an important
innate host response mechanism that clears bacteria
from the bloodstream when transient bacteremia occurs
Kullar
2011[16]
2005-2010
Single center (US)
320 MRSA blood culture Etest Vancomycin failure was associated with Etest MIC>1
(AOR 1.5), endocarditis (AOR 4.55), nosocomial
infection (AOR 2.19) and initial vancomycin
trough<15 mg/L (AOR 2).
Failure rates increased with vancomycin AUC/MIC:
61 %( AUC/MIC <421) vs. 48.6% (AUC/MIC>421.
Holmes
2011 [27]
2007-2008
27 sites Australia/NZ
532 SA blood culture
266 patients treated with
vancomycin
Etest
/BMD
Increased mortality associated with higher Etest MIC
12.2% (MIC≤1.5) vs. 26.8% (MIC>1.5).
Increased mortality with high vancomycin regardless
of methicillin susceptibility and treatment with either
vancomycin (OR 2.25) or flucloxacillin (OR 2.25).
High vancomycin MIC was associated with methi-
cillin resistance, hospital onset of infection, vanco-
mycin treatment, device associated infection and
death and increased incidence of sepsis.
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platelet microbicidal proteins has been shown to be an
important virulence factor in the ability to establish an
endovascular infection, like bacterial endocarditis.
In S. aureus, selection pressure by vancomycin in vivo and
in vitro co-selects for platelet microbicidal protein
resistance [38]. Thus, a vancomycin MIC creep seen in
MRSA from patients previously treated with vancomycin
carries with it consequences that extend beyond vanco-
mycin susceptibility and pharmacodynamics. MRSA
with higher vancomycin MIC may be less susceptible
not only to daptomycin but also platelet microbicidal
proteins and potentially other antimicrobial peptides of
the innate host response. The downstream consequences
of these phenotypes, including the risk of endocarditis in
patients previously treated with vancomycin, requires
further study.
It is an oversimplification, however, to say that S. aureus
strains with higher vancomycin MICs are more virulent, as
the virulence machinery of this pathogen is extremely
elegant and complex. In fact, there is evidence toward the
contrary when one considers traditional measures of
virulence, such as severity of illness as well as laboratory
invivomodels[39].Inonestudy,whilehighervancomycin
MICs were related to higher mortaility in MRSA bacter-
emia, vancomycin MIC was inversely related with symp-
toms of septic shock [40]. Other studies have shown that
while hVISA is associated with prolonged bacteremia, it is
inversely associated with mortality [41,42].
Conclusions
Using vancomycin as the cornerstone of MRSA therapy
for the past five decades, particularly in the last 20 years,
has exerted considerable selection pressure on S. aureus
strains in the healthcare setting. While > 99% of clinical
S. aureus isolates remain susceptible to vancomycin, the
vancomycin MIC creep seen in many institutions
demonstrates that this organism has not remained inert
to this pressure. While appearing subtle by the relatively
crude assays used in clinical microbiology laboratories,
evidence is emerging suggesting that the vancomycin
MIC creep is just the tip of the iceberg with regards to
clinical consequences. Further complicating the matter is
the variability in vancomycin MIC obtained between
agar-based Etest and broth microdilutions, both auto-
mated and manual.
Physicians and pharmacists are meeting these challenges in
a variety of ways, including: i) the adoption of rapid
molecular tests to quickly differentiate MRSA from beta-
lactam susceptible strains and, therefore, convert patients
with the latter more rapidly to superior beta-lactam
therapy; ii) optimization of vancomycin doses; iii) switch-
ing early to alternative agents when vancomycin MIC is
2 mg/L; iv) using combination antibiotic therapy; and
v) abandoning vancomycin altogether in serious MRSA
infections.
While all of these have theoretical benefits and, in some
single center experiences, have actually shown benefit,
the case for global generalizability of these counter-
measures remains unproven. Vancomycin has yet to be
demonstrated to be inferior to any of the novel agents
against MRSA bacteremia in prospective multi-center
studies. This may reflect the fact that many clinical trials
exclude the extremely difficult circumstances where
enhanced activity in laboratory settings of novel agents
may translate into a clinical benefit. Trials examining
subgroups of patients representative of these most
difficult cases would be extremely difficult to perform.
Many questions remain unanswered and the bridge
between laboratory science and clinical medicine is still
in the early stages of development. What is clear is that S.
aureus infections will remain a challenge for years to
come for physicians, microbiologists, pharmacists,
scientists, and, most importantly, patients.
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